New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For INTC;GOOG;FRX;VMW;GILD;EMC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 7, 2015
09:57 EDTINTCAltera negotiations with Intel continue, says dealReporter
Subscribe for More Information
07:03 EDTGOOGCyrusOne announces direct connectivity to Google Cloud Platform
Subscribe for More Information
06:46 EDTGOOGApple Pay, Google Wallet could see competition from CurrentC, Macworld says
Subscribe for More Information
06:25 EDTGOOGGroups urge authorities to probe YouTube app, Reuters says
Advocacy groups say they will urge federal regulators to probe a video app for Google's YouTube, according to Reuters. Aimed at children, the app deceptively blends video programming and ads, the news service quoted the groups as saying. Reference Link
06:21 EDTGOOGGoogle Ventures leading $12M investment in CoreOS, Business Insider reports
Subscribe for More Information
06:00 EDTGOOGTurkey restores access to YouTube, Twitter, Facebook, FT reports
Subscribe for More Information
April 6, 2015
19:42 EDTGOOGSurvey of iPhone, iPad users indicates preference for Google search, BI says
48% of Apple (AAPL) iPhone and iPad users report that if Yahoo (YHOO) were to acquire default search engine rights for Apple's Safari browser, they would manually switch the default search back to Google (GOOG), reports Business Insider, citing a survey of roughly 500 Apple users by Goldman Sachs tech analysts. 4% of the surveyed users stated they would intentionally keep Yahoo as the default. Reference Link
17:01 EDTINTCIntel to change financial reporting structure
Subscribe for More Information
10:39 EDTINTCQualcomm falls amid uncertainty about content in flagship Samsung phone
Subscribe for More Information
10:02 EDTVMWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:56 EDTGOOGGoogle in talks with Hutchison for cheaper overseas calls, Telegraph reports
Subscribe for More Information
09:36 EDTGOOGActive equity options trading on open
Subscribe for More Information
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
06:35 EDTVMWVMware upgraded to Buy from Neutral at Nomura
Nomura upgraded VMware to Buy with a $95 price target following favorable survey results. The firm's Q1 survey came in slightly ahead of plan and believes the Street is too cautious on shares, which could serve as a positive catalyst for shares. Separately, Nomura said the upcoming end of Windows Server 2003 in July could be an incremental catalyst as replacement servers will likely be virtualized.
06:32 EDTGOOGGoogle Ventures-backed Buttercoin to shut down
Subscribe for More Information
05:54 EDTGOOGYouTube planning advertising campaign aimed at Canada, Globe and Mail says
Subscribe for More Information
05:43 EDTVMWVMware upgraded to Buy from Neutral at Nomura
April 5, 2015
16:56 EDTGOOGEU considers major probe into Internet platforms, WSJ says
Subscribe for More Information
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
14:32 EDTGOOGAntitrust suit against Google over Android app limits dropped, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use